Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study

US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.

The US FDA is pushing ahead with a study of deceptive drug promotion, refuting the Pharmaceutical Research and Manufacturers of America's contention that the issue is not a prevalent problem and that evaluating the ability of consumers and healthcare professionals to detect such ads would offer "limited practical utility."

Without mentioning PhRMA by name, FDA responded to its criticisms in a discussion of comments the agency received about its...